Tag Archives: Depomed

August, 2018

3 August
PDL BioPharma Acquires Depomed’s Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

INCLINE VILLAGE, Nev., Aug. 2, 2018 /PRNewswire/ — PDL BioPharma, Inc. (“PDL”) (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the “Royalty Agreement”) with Depomed, Inc. (“Depomed”) under which PDL acquired all of Depomed’s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20 million. Under …
Share

8 July
Horizon Pharma Offers to Acquire Depomed in a $3 Billion Deal

DUBLIN, IRELAND — (Marketwired) — 07/07/15 — Horizon Pharma plc (NASDAQ: HZNP) Transaction would generate significant revenue and operating synergies, tax savings and would also be immediately and substantially accretive to Horizon’s adjusted diluted earnings per share Projected full-year pro forma combined 2015 net sales and adjusted EBITDA would be …
Share